Learning Objectives
Upon completion of this activity, participants should be able to:
- Apply clinical trial data on the incidence and severity of adverse events associated with chemotherapy agents to optimize management of patient symptoms
- Employ appropriate prophylactic measures and treatment monitoring during targeted agent therapy for non-Hodgkin’s lymphoma patients based on unique toxicities associated with each agent
- Describe appropriate posttreatment safety measures and dosing regimens required when monitoring patients receiving radioimmunotherapy agents
- Identify critical safety and dosing issues associated with the use of therapeutic agents for the treatment of non-Hodgkin’s lymphomas
Topics covered include:
- Overview of Treatment Considerations for Patients With Non-Hodgkin’s Lymphoma
- Chemotherapy and Adverse Events in NHL
- Alkylating Agents: Dosing and Adverse Events
- Anthracyclines: Dosing and Adverse Events
- Antimetabolites: Dosing and Adverse Events
- Vincristine: Dosing and Adverse Effects
- Etoposide: Dosing and Adverse Events
- Intrathecal Chemotherapy
- Nonimmunologic Targeted Agents for the Treatment of NHL
- Bexarotene: Dosing and Adverse Events
- Vorinostat: Dosing and Adverse Events
- L-Asparaginase: Dosing and Adverse Events
- Interleukin-2 and 12: Dosing and Adverse Events
- Monoclonal Antibodies for the Treatment of NHL
- Radioimmunotherapy for the Treatment of Non-Hodgkin’s Lymphoma
- Immunomodulatory Agents for Non-Hodgkin’s Lymphoma
- Interferon alfa: Dosing and Adverse Events
- Conclusion
Abstract